Vol. 150, No. 29 — July 16, 2016

GOVERNMENT NOTICES

DEPARTMENT OF ENVIRONMENT AND CLIMATE CHANGE

SPECIES AT RISK ACT

Description of Bent Spike-rush, Great Lakes Plains population critical habitat, in Long Point National Wildlife Area

The Bent Spike-rush (Eleocharis geniculata), Great Lakes Plains population, is listed on Schedule 1 of the Species at Risk Act. In Canada, the Bent Spike-rush, Great Lakes Plains population, is found on the shorelines of ponds and lakes in southern Ontario.

The Recovery Strategy for the Bent Spike-rush (Eleocharis geniculata), Great Lakes Plains population in Canada, available at www.registrelep.gc.ca/species/speciesDetails_e.cfm?sid=1042#ot10, identifies the critical habitat for the species in a number of areas, including within a federally protected area.

Notice is hereby given that, pursuant to subsection 58(2) of the Species at Risk Act, subsection 58(1) of that Act applies, 90 days after publication of this notice, to the critical habitat of the Bent Spike-rush, Great Lakes Plains population — identified in the recovery strategy for that species that is included on the Species at Risk Public Registry — that is found within Long Point National Wildlife Area, described in Schedule 1 of the Wildlife Area Regulations made pursuant to the Canada Wildlife Act.

July 4, 2016

MARY JANE ROBERTS
Director
Species at Risk Act Management and
Regulatory Affairs
Canadian Wildlife Service

[29-1-o]

DEPARTMENT OF HEALTH

FOOD AND DRUGS ACT

Interim Order Respecting Naloxone Hydrochloride Nasal Spray

Whereas the Minister of Health believes that immediate action is required to deal with a significant risk, direct or indirect, to health, safety or the environment;

Therefore, the Minister of Health, pursuant to subsection 30.1(1) (see footnote a) of the Food and Drugs Act (see footnote b), makes the annexed Interim Order Respecting Naloxone Hydrochloride Nasal Spray.

Ottawa, July 5, 2016

Jane Philpott
Minister of Health

Interim Order Respecting Naloxone Hydrochloride Nasal Spray

Interpretation

Definitions

1 The following definitions apply in this Interim Order.

naloxone hydrochloride nasal spray means the drug naloxone hydrochloride nasal spray 4 mg that is approved for sale in the United States and identified in that country by the brand name NARCAN® Nasal Spray. (vaporisateur nasal de chlorhydrate de naloxone)

Regulations means the Food and Drug Regulations. (Règlement)

Words and expressions

2 Unless the context requires otherwise, words and expressions used in this Interim Order have the same meaning as in the Regulations.

Purpose

Importation and sale

3 The purpose of this Interim Order is to permit the immediate importation and sale, including the distribution, of naloxone hydrochloride nasal spray for use in the emergency treatment of known or suspected opiod overdose.

Non-application

Importation

4 The provisions in the Regulations respecting importation do not apply to the importation of naloxone hydrochloride nasal spray if

Sale

5 The provisions in the Regulations respecting sale and distribution do not apply to the sale or distribution of naloxone hydrochloride nasal spray if each package of the spray that is sold or distributed is identified by a label that bears the NDC 69547-353-02 and if the package is accompanied by the label referred to in paragraph 4(c), by the French version of that label, published by the Minister of Health, and by the document Important Supplementary Information for NARCAN® Nasal Spray 4 mg, published in 2016 by the Minister of Health, in English and French.

Part C of Regulations

6 Subject to sections 7 and 8, the provisions of Part C of the Regulations do not apply in respect of the naloxone hydrochloride nasal spray that is referred to in sections 4 and 5.

Application of Certain Provisions of the Regulations

Prohibition — sale

7 (1) Subject to subsection (2), the prohibition set out in section C.01.016 of the Regulations applies to the sale of the naloxone hydrochloride nasal spray that is referred to in sections 4 and 5.

Serious adverse drug reaction reporting

(2) The manufacturer of the spray is required to comply only with the requirement set out in section C.01.017 of the Regulations.

Recalls

8 Section C.01.051 of the Regulations applies in respect of the naloxone hydrochloride nasal spray that is referred to in sections 4 and 5.

EXPLANATORY NOTE

(This note is not part of the Interim Order.)

Proposal

The Order approves the Interim Order Respecting Naloxone Hydrochloride Nasal Spray (the Interim Order) made by the Minister of Health on July 5, 2016. Without this approval, the Interim Order would, in accordance with paragraph 30.1(2)(a) of the Food and Drugs Act, cease to have effect 14 days after it was made.

The Interim Order authorizes the immediate importation and sale of NARCAN® Nasal Spray for use in the emergency treatment of known or suspected opioid overdoses.

In order to be sold in Canada, NARCAN® Nasal Spray will need to be accompanied by the U.S. labelling as well as additional information required by the Minister of Health. This additional information includes instructions for use in French and instructions on how to report adverse drug reactions. This additional information will also be made available on the Health Canada Web site.

The provisions in Part C of the Food and Drug Regulations will not apply to the importation or sale of NARCAN® Nasal Spray, other than the requirements relating to the reporting of serious adverse drug reactions and recall by the manufacturer.

NARCAN® Nasal Spray will be available without a prescription.

As a result of this approval, the Interim Order will, in accordance with paragraphs 30.1(2)(b) to (d) of the Food and Drugs Act, cease to have effect on the day on which it is repealed, on the day on which regulations having the same effect come into force, or one year after the day on which the Interim Order is made, whichever is earliest.

Objective

The objective of this Interim Order is to take immediate action to address the significant risk to the health of Canadians as a result of opioid overdoses. This Interim Order represents one of a number of actions to combat the risks associated with opioid use, announced by the Minister of Health on June 17, 2016, at the Charting the Future of Drug Policy in Canada conference.

Background

Drug overdose deaths as a result of opioid use and abuse are continuing to rise in Canada. Opioids are a class of drugs that include prescription medications such as oxycodone, fentanyl, hydrocodone, and morphine, as well as illegal drugs such as heroin. The continuing rise in drug overdose deaths in British Columbia led to the declaration of a public health emergency on April 14, 2016. In January alone, there were 74 overdose deaths in that province, and if the trend continues, the total number of deaths could far exceed the 474 deaths that occurred in 2015. Similar disturbing increases have been observed across Canada, much of it as a result of the illicit use of prescription medications.

Naloxone hydrochloride is a life-saving medication that can stop or reverse the effects of an opioid overdose. It is currently available in Canada in a form that requires it to be administered by injection. Health Canada has recently taken steps to make naloxone hydrochloride available without a prescription in emergency situations outside of hospitals.

Naloxone hydrochloride is available in the United States (U.S.) in both an injectable form and as a nasal spray sold by the brand name NARCAN® (National Drug Code 69547-353-02). NARCAN® Nasal Spray is ready-to-use and does not require assembly, can be used on adults or children, and is easily administered by anyone, even those without medical training.

In approving the nasal spray, the U.S. Food and Drug Administration (FDA) noted that many first responders and primary caregivers felt that a nasal spray formulation of naloxone hydrochloride is easier to deliver, and eliminates the risk of a contaminated needle stick.

NARCAN® Nasal Spray is not currently available for sale in Canada. However, its manufacturer, Adapt Pharma Inc., has filed a new drug submission with Health Canada that could eventually allow for its sale in Canada. Until this occurs, the Minister of Health has determined that there is an immediate need for the product to be available in Canada to help address the ongoing health emergency that exists as a result of opioid overdoses.

Implications

This Interim Order will have the effect of providing Canadians with earlier access to a safe and effective drug that is easy to use by persons who are not medically trained and could subsequently save additional lives by reversing the effect of opioid overdose. It could also reduce the risks of infection from contaminated needle sticks to police, first responders, and other health care professionals who may currently be administering naloxone hydrochloride by injection.

Consultation

Representatives of provinces and territories, including chief medical officers of health and other health professionals, have been made aware of the Minister’s intent to take action to reduce the risk of opioid overdose in Canada, including measures to make naloxone hydrochloride more accessible to Canadians at risk. They have indicated their support for the Interim Order as a means to provide earlier access to a safer and easier to use nasal formulation.

Contact

Bruno Rodrigue
Policy, Planning and International Affairs Directorate
Health Products and Food Branch
Health Canada
Address Locator: 3105A
Holland Cross, Tower B, 5th Floor
1600 Scott Street
Ottawa, Ontario
K1A 0K9
Email: LRM_MLR_consultations@hc-sc.gc.ca

[29-1-o]

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Decisions, undertakings and orders on claims for exemption

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the decisions of the screening officer respecting each claim for exemption and the relevant material safety data sheet (MSDS) and (where applicable) the label listed below.

In accordance with section 20 of the Hazardous Materials Information Review Act, a claimant or any affected party, as defined, may appeal a decision or order of a screening officer. An affected party may also appeal an undertaking in respect of which a notice has been published in the Canada Gazette. To initiate the appeal process, a Statement of Appeal (Form 1) as prescribed by the Hazardous Materials Information Review Act Appeal Board Procedures Regulations must be completed and delivered, along with the fee prescribed by section 12 of the Hazardous Materials Information Review Regulations, within 45 days of the publication of this notice in the Canada Gazette, Part I, to the Chief Appeals Officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 4th Floor, Ottawa, Ontario K1A 0K9.

ROSSLYNN MILLER-LEE
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended, and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015 and the former legislation (HPA/CPR) is referred to as WHMIS 1988.

Transitional provisions allow compliance with either WHMIS 1988 or WHMIS 2015 for a specified period of time. All claims for exemption in this publication were filed and evaluated in accordance with the provisions of WHMIS 1988.

There were no written representations from affected parties with respect to any of the claims for exemption and related MSDSs or labels mentioned below.

Each of the claims for exemption listed in the table below was found to be valid except for those for Registry Numbers (RNs) 9494, 9537, 9548, 9583, 9589, 9616, 9655, 9656 and 9658, which were found to be partially valid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.

Claimant

Product Identifier

RN

Date of Decision

Champion Technologies Ltd.

Emulsotron X-8645

9222

2016-01-13

Champion Technologies Ltd.

Emulsotron X-8572

9228

2016-01-13

Fusion Technologies Inc.

CupBuster-1

9341

2016-02-15

GE Water & Process Technologies Canada

SCALETROL* PDC9489

9494

2016-02-18

GE Water & Process Technologies Canada

FUELSOLV* SOX102

9495

2016-03-17

Momentive Performance Materials

Niax* Silicone L-655

9537

2016-01-28

Nalco Canada ULC

METRIX™ 64111

9538

2016-01-25

Nalco Canada ULC

METRIX™ 64112

9539

2016-01-25

Nalco Canada ULC

RDS-78

9542

2016-01-29

Secure Energy Services Inc.

SECURE PA-745

9546

2016-01-25

Momentive Performance Materials

Silform* INX

9547

2016-02-01

Momentive Performance Materials

Niax* Silicone Y-16270

9548

2016-02-01

Lubrizol Specialty Products, Inc.

EP™ 2000 Flow Improver

9549

2016-02-01

Ingevity Corporation, formerly MeadWestvaco Corp. Specialty Chemicals Div.

INDULIN® CBA-5

9552

2016-01-08

Nalco Canada ULC

Clean n Cor® EC1538A

9556

2016-02-01

Ingevity Corporation, formerly MeadWestvaco Corp. Specialty Chemicals Div.

EVOFLEX™ CA-2

9557

2016-01-05

Hexion Inc.

EPON™ RESIN 233

9563

2016-02-03

Hexion Inc.

EPIKURE™ CURING AGENT 3393

9564

2016-02-03

Akzo Nobel Surface Chemistry LLC

REDICOTE® E-11 E

9565

2016-01-28

GE Water & Process Technologies Canada

THERMOFLO* 7041

9570

2016-03-17

GE Water & Process Technologies Canada

PROSWEET* S1794

9571

2016-02-22

Baker Hughes Canada Company

TOPGUARD™ 1190C NEUTRALIZER

9572

2016-02-10

Baker Hughes Canada Company

TRETOLITE™ RBW747 WATER CLARIFIER

9573

2016-02-12

Nalco Canada ULC

EMBR17847A

9583

2016-02-24

Charles Tennant & Company (Canada) Limited

ABATED KAX 41 SOLUTION

9586

2016-01-04

Charles Tennant & Company (Canada) Limited

ABATED KAX 51 SOLUTION

9587

2016-01-04

Ingevity Corporation, formerly MeadWestvaco Corp. Specialty Chemicals Div.

INDULIN® XD-70

9588

2016-03-17

Engenium Chemicals Corporation

CAN-2064

9589

2016-02-18

Ingevity Corporation, formerly MeadWestvaco Corp. Specialty Chemicals Div.

INDULIN® JAK

9590

2016-02-23

Akzo Nobel Surface Chemistry LLC

REDICOTE® C-3082-2

9591

2016-01-08

Akzo Nobel Surface Chemistry LLC

REDICOTE® C-320

9592

2016-01-07

Allnex Canada Inc., (c/o Goodmans, LLP)

EBECRYL® 4200 radiation curing resins

9594

2016-01-14

Allnex Canada Inc., (c/o Goodmans, LLP)

EBECRYL® 4100 radiation curing resins

9595

2016-01-14

Allnex Canada Inc., (c/o Goodmans, LLP)

EBECRYL® 4150 radiation curing resins

9596

2016-01-14

Allnex Canada Inc., (c/o Goodmans, LLP)

EBECRYL® 4738 radiation curing resins

9597

2016-01-14

Akzo Nobel Surface Chemistry LLC

REDICOTE® 22805

9604

2016-01-07

Momentive Performance Materials

Silquest* AF-1 silane

9605

2016-02-08

Afton Chemical Corporation

Polartech MR 6000

9607

2016-02-05

Cytec Industries Inc.

CYASORB CYNERGY SOLUTIONS® A400 STABILIZER

9609

2016-01-20

Diacon Technologies Ltd.

CEDARBRITE

9616

2016-02-24

Momentive Performance Materials

Niax* Silicone L-590

9617

2016-03-30

Chevron Oronite Company LLC

OGA 72043

9618

2016-01-28

Chevron Oronite Company LLC

OGA 72040

9619

2016-01-28

Cytec Industries Inc.

AEROSOL® EF-810 Surfactant

9621

2016-01-12

Baker Hughes Canada Company

TOPGUARD™ 1242 CORROSION INHIBITOR

9622

2016-02-05

Cytec Industries Inc.

AEROSOL® EF-800 Surfactant

9623

2016-01-07

Evonik Corporation

Dynasylan® 6490

9624

2016-02-08

Baker Hughes Canada Company

RE32545PAO ASPHALTENE INHIBITOR

9632

2016-03-11

The Chemours Canada Company

Endimal® DW

9650

2016-02-10

Afton Chemical Corporation

HiTEC® 6579T Fuel Additive

9655

2016-02-12

Afton Chemical Corporation

HiTEC® 301 Performance Additive

9656

2016-01-28

Stepan Company

AGENT 3109-6

9658

2016-03-11

Engenium Chemicals Corporation

ShearMUL II

9660

2016-01-27

Nalco Canada ULC

NALCO® EC5494A

9668

2016-02-29

Nalco Canada ULC

APEX PF6500

9669

2016-02-29

Nalco Canada ULC

X-Corr LT

9676

2016-02-23

Nalco Canada ULC

X-Corr HT

9677

2016-02-23

Nalco Canada ULC

FFR4100

9678

2016-02-23

Nalco Canada ULC

64652

9679

2016-02-23

Nalco Canada ULC

NALCO® 64665

9680

2016-02-23

Momentive Performance Materials

UAX-6994 Silicone Surfactant

9683

2016-02-29

Engenium Chemicals Corporation

Mudco-Mul II

9684

2016-02-29

GE Water & Process Technologies Canada

PROSWEET* S1765

9688

2016-02-29

Nalco Canada ULC

CLAR10670A

9693

2016-03-30

Afton Chemical Corporation

HiTEC® 510 Performance Additive

9715

2016-02-23

The subject of the claim on which the screening officer issued a decision for the following claims is different from the subject of the claim that was published in the Notice of Filing.

RN

Notice of Filing Publication Date

Original Subject of the Claim

Revised Subject of the Claim

9544

2015-07-25

C.i. and c. of three ingredients

C.i. and c. of three ingredients, c. of two ingredients

9583

2015-11-07

C.i. and c. of two ingredients

C.i. and c. of two ingredients, c. of five ingredients

9609

2015-11-07

C.i. and c. of three ingredients

C.i. and c. of two ingredients

9650

2015-11-07

C.i. and c. of one ingredient

C.i. and c. of one ingredient, c. of one ingredient

9653

2015-11-07

C.i. and c. of five ingredients

C.i. and c. of seven ingredients, c. of one ingredient

9655

2015-11-07

C.i. and c. of three ingredients

C.i. and c. of six ingredients, c. of three ingredients

9669

2016-01-23

C.i. of one ingredient

C.i. of one ingredient, c.i. and c. of one ingredient

9676

2016-01-23

C.i. of four ingredients

C.i. and c. of five ingredients, c. of two ingredients

9677

2016-01-23

C.i. of two ingredients

C.i. and c. of four ingredients, c. of two ingredients

9678

2016-01-23

C.i. of two ingredients

C.i. and c. of one ingredient, c. of one ingredient

9679

2016-01-23

C.i. of two ingredients

C.i. and c. of three ingredients

9680

2016-01-23

C.i. of two ingredients

C.i. and c. of three ingredients

9693

2016-01-23

C.i. and c. of two ingredients

C.i. and c. of three ingredients

Note: C.i. = Chemical identity and c. = concentration

Having regard for the various data readily available in the literature and any information provided by the claimant, the screening officer found that only the respective MSDSs in respect of the claims bearing RNs 9542, 9590, 9624 and 9715 complied with the requirements of the relevant legislation.

In all cases where the MSDS or the label was determined not to be in compliance with the relevant legislation, pursuant to subsection 16.1(1) of the Hazardous Materials Information Review Act, the claimant was given 30 days to provide the screening officer with a signed undertaking accompanied by the MSDS or the label amended as necessary.

CLAIMS FOR WHICH THE SCREENING OFFICER WAS SATISFIED THAT THE CLAIMANT HAD TAKEN THE MEASURES SET OUT IN THE UNDERTAKING

Pursuant to paragraph 18(1)(b) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that has been disclosed on the relevant MSDS or label in compliance with an undertaking and the date on which the notice referred to in subsection 16.1(3) of the Act was issued.

RN: 9222 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose ingestion and eye contact as additional routes of entry.
  2. Disclose the presence of two additional confidential ingredients, “oxyalkylated amine” and “oxyalkylated polymer”.
  3. Disclose that an ingredient has been shown to cause teratogenic effects in the presence and absence of maternal toxicity in animals.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

RN: 9228 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose ingestion and eye contact as additional routes of entry.
  2. Disclose the presence of two additional confidential ingredients, “oxyalkylated amine” and “oxyalkylated polymer”.
  3. Disclose that an ingredient has been shown to cause teratogenic effects in the presence and absence of maternal toxicity in animals.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D1B and D2A.

RN: 9341 Date: 2016-03-24

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose ingestion as an additional route of entry.
  2. Disclose that an ingredient has been shown to be corrosive to the skin.
  3. Disclose an acceptable TWA exposure limit for the confidential ingredients “alkyl aromatic” and “halogenated acid”.
  4. Disclose an acceptable TWA and STEL exposure limit for the confidential ingredient “chlorinated alkene”.
  5. Disclose the appropriate LD50 values (oral and dermal) for the confidential ingredients “alkyl aromatic”, “chlorinated alkene” and “halogenated acid”, in an acceptable manner.
  6. Disclose an LC50 (rat, vapour, 4 hours) value of 19 mg/L for the confidential ingredient “alkyl aromatic”.
  7. Disclose that chronic exposure to an ingredient has been shown to cause persistent mid-frequency hearing loss in animals.
  8. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.
  9. Disclose that an ingredient has been shown to cause carcinogenic effects.
  10. Disclose that an ingredient has been shown to cause teratogenic effects in the presence of maternal toxicity.
  11. Disclose that the confidential ingredient “alkyl aromatic” is toxicologically synergistic with “n-hexane”.
  12. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes B2 and D2A.

RN: 9495 Date: 2016-04-27

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RNs: 9538 and 9539 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9546 Date: 2016-01-28

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.
  2. Disclose the additional WHMIS pictogram for class D1, if WHMIS pictograms are shown on the MSDS.
  3. Disclose that the ingredient “xylene” is toxicologically synergistic with “n-hexane”.
  4. Disclose the concentrations of the ingredients “methanol”, “xylene” and the confidential ingredient “polyalkoxylated alcohol”.
  5. Disclose the appropriate LD50 values (oral) for the ingredients “methanol”, “xylene” and the confidential ingredient “polyalkoxylated alcohol”, in an acceptable manner.

RN: 9547 Date: 2016-05-24

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9549 Date: 2016-04-04

The claimant had been advised to amend certain aspects of the content of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and concentration, or concentration range, in the product.
  2. Disclose the exposure limit for the ingredient “C11-C15 hydrocarbon solvent” and that it has been classified as a suspected human carcinogen (A3) by ACGIH.
  3. Disclose an LD50 (rat, oral) value of 4 g/kg and an LD50 (rabbit, dermal) value of 9.53 mL/kg for the ingredient “ethylene glycol”.
  4. Disclose an LD50 (rat, oral) value of 977 mg/kg for the ingredient “sodium lauryl sulfate”.

RN: 9552 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9556 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the ACGIH “skin” notation for the ingredient “2-mercaptoethyl alcohol”.
  2. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.
  3. Disclose an LD50 (rat, oral) value of 6.0 mL/kg for the ingredient “isopropanol”.
  4. Disclose an LC50 (rat, vapour, 8 hours) value of 19 000 ppm for the ingredient “isopropanol”.

RN: 9557 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin sensitization in animals.
  2. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2B.

RN: 9565 Date: 2016-02-10

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an ACGIH–STEL exposure limit of 1 000 ppm for the ingredient “ethanol”.
  2. Disclose an acceptable LD50 (rat, oral) value for the confidential ingredient “quaternary ammonium salts”.
  3. Disclose an LC50 (rat, vapour, 4 hours) value of 117 mg/L for the ingredient “ethanol”.
  4. Disclose that acute ingestion of an ingredient has been shown to cause damage to the digestive tract in animals and central nervous system effects in animals and humans.
  5. Disclose that the ingredient “ethanol” has been classified as a suspected human carcinogen (A3) by ACGIH.
  6. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

RN: 9570 Date: 2016-04-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin sensitization in animals.

RN: 9571 Date: 2016-04-01

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that acute ingestion of an ingredient has been shown to cause kidney effects in humans.
  2. Disclose that chronic ingestion of an ingredient has been shown to cause liver and kidney effects in animals.
  3. In relation to the first aid information shown on the MSDS for eye contact, disclose a statement to the effect that medical advice should be obtained.

RN: 9572 Date: 2016-03-29

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that contaminated clothing should be removed immediately.
  2. Disclose an LD50 (rat, oral) value of 1 450 mg/kg for the ingredient “morpholine”.
  3. Disclose an LD50 (rabbit, dermal) value of 1.37 mL/kg for the ingredient “ethanol, 2-(dimethyl amino-)”.
  4. Disclose an LD50 (rabbit, dermal) value of 0.5 mL/kg for the ingredient “morpholine”.
  5. Disclose an LC50 (rat, vapour, 4 hours) value of 3.7 mg/L for the ingredient “N-butylamine”.

RN: 9573 Date: 2016-04-04

The claimant had been advised to amend certain aspects of the content of the MSDS.

RN: 9586 Date: 2016-02-02

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an acceptable TWA and STEL exposure limit for the confidential ingredient “proprietary amine derivative 1”.
  2. Disclose an acceptable STEL exposure limit for the confidential ingredient “proprietary amine derivative 2”.
  3. Disclose an LD50 (mouse, oral) value of 480 mg/kg for the ingredient “potassium isobutyl xanthate”.
  4. Disclose an LD50 (rat, oral) value of 50–500 mg/kg and an LC50 (rat, vapour, 4 hours) value of >2.5 mg/L for the confidential ingredient “proprietary amine derivative 2”.
  5. Disclose an LD50 (rat, oral) value of >500 mg/kg, an LD50 (rabbit, dermal) value of >200–1 000 mg/kg and an LC50 (rat, vapour, 4 hours) value of >2 500 ppm for the confidential ingredient “proprietary amine derivative 1”.
  6. Disclose that an ingredient has been shown to be corrosive to the eyes and to the skin.

RN: 9587 Date: 2016-02-02

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an acceptable TWA and STEL exposure limit for the confidential ingredient “proprietary amine derivative 1”.
  2. Disclose an acceptable STEL exposure limit for the confidential ingredient “proprietary amine derivative 2”.
  3. Disclose an LD50 (rat, oral) value of >500 mg/kg, an LD50 (rabbit, dermal) value of >200–1 000 mg/kg and an LC50 (rat, vapour, 4 hours) value of >2 500 ppm for the confidential ingredient “proprietary amine derivative 1”.
  4. Disclose an LD50 (rat, oral) value of 50–500 mg/kg and an LC50 (rat, vapour, 4 hours) value of >2.5 mg/L for the confidential ingredient “proprietary amine derivative 2”.
  5. Disclose that an ingredient has been shown to be corrosive to the eyes and to the skin.

RN: 9588 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the content of the MSDS.

RN: 9591 Date: 2016-02-01

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that acute ingestion of an ingredient has been shown to cause central nervous system effects in humans.
  2. Disclose that an ingredient has been shown to cause skin sensitization in animals.
  3. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2B.

RN: 9592 Date: 2016-02-01

The claimant had been advised to amend certain aspects of the content of the MSDS.

RN: 9594 Date: 2016-02-12

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of carbon” and “oxides of nitrogen” to the list of hazardous decomposition products.

RN: 9595 Date: 2016-02-12

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9596 Date: 2016-02-12

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of carbon” and “oxides of nitrogen” to the list of hazardous decomposition products.

RN: 9597 Date: 2016-02-12

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9604 Date: 2016-02-01

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be corrosive to the skin.
  2. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class E.

RN: 9605 Date: 2016-02-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9607 Date: 2016-03-01

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, “castor oil soap (II)”.

RN: 9609 Date: 2016-02-09

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, “substituted triazine”.

RN: 9617 Date: 2016-04-06

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RNs: 9618, 9619 and 9620 Date: 2016-02-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9622 Date: 2016-03-29

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose ingestion as an additional route of entry.

RN: 9623 Date: 2016-01-28

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9632 Date: 2016-04-04

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose ingestion as an additional route of entry.

RN: 9650 Date: 2016-03-31

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9660 Date: 2016-02-01

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin sensitization in animals.

RN: 9668 Date: 2016-03-30

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an acceptable LD50 (rat, oral) value for the confidential ingredient “substituted alkylamine”.
  2. Disclose that an ingredient has been shown to cause skin sensitization in animals.

RN: 9669 Date: 2016-03-30

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, “acrylamide modified polymer”.

RN: 9676 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that acute ingestion of an ingredient has been shown to cause coma and low blood pressure in humans.
  2. Disclose the presence of an additional confidential ingredient, “fatty amino compound salt”.
  3. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that contaminated clothing should be removed immediately.
  4. Disclose a statement to the effect that metal containers should be grounded during the transfer of large quantities of the product.
  5. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.
  6. Disclose an LD50 (rat, oral) value of 6.0 mL/kg for the ingredient “isopropanol”.
  7. Disclose an LD50 (rat, oral) value of 1 600 mg/kg for the confidential ingredient “aromatic aldehyde”.
  8. Disclose an LC50 (rat, inhalation, 8 hours) value of 19 000 ppm for the ingredient “isopropanol”.
  9. Disclose an acceptable LD50 (rabbit, dermal) value for the confidential ingredient “aromatic aldehyde”.

RN: 9677 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that acute ingestion of an ingredient has been shown to cause coma and low blood pressure in humans.
  2. Disclose that acute inhalation of an ingredient has been shown to cause central nervous system effects in animals.
  3. Disclose the presence of two additional confidential ingredients, “fatty amino compound salt” and “fatty alkyl polyglycol”.
  4. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that contaminated clothing should be removed immediately.
  5. Disclose a statement to the effect that metal containers should be grounded during the transfer of large quantities of the product.
  6. Disclose that an ingredient has been shown to cause mutagenic effects, in vitro.
  7. Disclose an LD50 (rat, oral) value of 6.0 mL/kg and an LC50 (rat, inhalation, 8 hours) value of 19 000 ppm for the ingredient “isopropanol”.
  8. Disclose an LD50 (rat, oral) value of 1 600 mg/kg for the confidential ingredient “aromatic aldehyde”.
  9. Disclose an acceptable LD50 (rabbit, dermal) value for the confidential ingredient “aromatic aldehyde”.

RN: 9678 Date: 2016-03-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential ingredient, “acrylamide modified polymer”.
  2. Disclose the presence of an additional ingredient, along with its CAS registry number and its concentration, or concentration range, in the product.
  3. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that contaminated clothing should be removed immediately.
  4. Disclose that an ingredient has been shown to cause skin irritation.

RN: 9679 Date: 2016-03-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin irritation.
  2. Disclose the presence of an additional confidential ingredient, “fatty acid”.
  3. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that contaminated clothing should be removed immediately.
  4. Disclose that an ingredient has been shown to cause skin sensitization in animals.
  5. Disclose an acceptable LD50 (rat, oral) value for the confidential ingredient “oxyalkylated alcohol 2”.
  6. Disclose an acceptable LD50 (rabbit, dermal) value for the confidential ingredient “oxyalkylated alcohol”.

RN: 9680 Date: 2016-03-22

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin irritation.
  2. Disclose the presence of an additional confidential ingredient, “fatty acid”.
  3. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that contaminated clothing should be removed immediately.
  4. Disclose that an ingredient has been shown to cause skin sensitization in animals.
  5. Disclose an acceptable LD50 (rat, oral) value for the confidential ingredient “oxyalkylated alcohol 2”.
  6. Disclose an acceptable LD50 (rabbit, dermal) value for the confidential ingredient “oxyalkylated alcohol”.

RN: 9683 Date: 2016-03-07

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of two additional confidential ingredients, “polyether polyol” and “siloxane polyalkyleneoxide copolymer (2)”.

RN: 9684 Date: 2016-03-03

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause skin sensitization in animals.

RN: 9688 Date: 2016-03-31

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be corrosive to the skin.
  2. Disclose an acceptable LD50 (rat, oral) value for the confidential ingredient “amino ether”.
  3. Disclose that an ingredient has been shown to cause teratogenic and embryotoxic effects in the absence of maternal toxicity.
  4. Disclose that an ingredient has been shown to cause reproductive toxicity in animals.
  5. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.

RN: 9693 Date: 2016-04-21

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be corrosive to the skin.
  2. Disclose the presence of an additional confidential ingredient, “oxyalkylated resin”.
  3. Disclose a statement to the effect that metal containers should be grounded during the transfer of large quantities of the product.
  4. Disclose ingestion as an additional route of entry.
  5. Disclose an LC50 (rat, vapour, 4 hours) value of 29 mg/L for the ingredient “xylene”.

CLAIMS FOR WHICH THE SCREENING OFFICER ORDERED THE CLAIMANT TO COMPLY WITH THE APPLICABLE DISCLOSURE REQUIREMENTS

In the case of the following claims, either the claimant did not supply the screening officer with a signed undertaking or the screening officer was not satisfied that the claimant had taken the measures set out in the undertaking in the manner and within the period specified in it. Pursuant to subsection 17(1) of the Hazardous Materials Information Review Act, the screening officer ordered the claimant to comply with the requirements of the relevant legislation within 30 days from the expiry of the appeal period, except that the information in respect of which the claim for exemption was made does not have to be disclosed, and to provide a copy of the amended MSDS to the screening officer within 30 days of expiry of the appeal period.

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on the MSDS reviewed by the screening officer and the date of the order.

RN: 9563 Date: 2016-03-07

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to be corrosive to the eyes.
  2. Disclose that ingredients have been shown to cause mutagenic effects, in vitro.
  3. Disclose that an ingredient has been shown to cause skin sensitization in animals.

RN: 9564 Date: 2016-03-07

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an acceptable TWA exposure limit for the confidential ingredient “aromatic alcohol”.
  2. Disclose information on personal protective equipment to be used for the hands in an acceptable manner.
  3. Disclose that an ingredient has been shown to cause skin sensitization in animals.
  4. Disclose that an ingredient has been shown to be corrosive to the skin.
  5. Disclose that an ingredient has been shown to be corrosive to the eyes.
  6. Disclose that an ingredient has been shown to cause teratogenic effects in the absence of maternal toxicity.

CLAIMS FOR WHICH THE SCREENING OFFICER ISSUED THE DECISION THAT THE CLAIM FOR EXEMPTION WAS EITHER PARTIALLY VALID OR INVALID

In the case of the following claims, the screening officer issued the decision that the claims for exemption were partially valid.

Pursuant to section 18 of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on an MSDS or a label pursuant to subsection 16(1) and information that has been disclosed on the relevant MSDS or label in compliance with an undertaking, and the dates on which the orders and notices referred to in subsection 16.1(3) of the Act were issued.

RN: 9494

Date of compliance undertaking: 2016-04-01

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9537

Date of compliance undertaking: 2016-04-06

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional ingredient, along with its CAS registry number and concentration, or concentration range, in the product.
  2. Disclose an LC50 (rat, aerosol, 4 hours) value of 8.67 mg/L for the ingredient “decamethylcyclopentasiloxane”.
  3. Disclose that chronic inhalation of an ingredient has been shown to cause liver and kidney effects in animals.

RN: 9548

Date of compliance undertaking: 2016-05-24

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

RN: 9583

Date of compliance undertaking: 2016-03-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose a statement to the effect that metal containers should be grounded during the transfer of large quantities of the product.
  2. Disclose acceptable LD50 (rat, oral) and LD50 (rabbit, dermal) values for the product.
  3. Disclose that an ingredient has been shown to cause teratogenic effects in the absence of maternal toxicity in animals.
  4. Disclose an LC50 (rat, vapour, 4 hours) value of 29 mg/L for the ingredient “xylene”.
  5. Disclose an LC50 (rat, vapour, 8 hours) value of 19 000 ppm for the ingredient “isopropanol”.
  6. Disclose that the ingredient “xylene” is toxicologically synergistic with “n-hexane”.

RN: 9589

Date of compliance undertaking: 2016-03-29

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient has been shown to cause teratogenic and embryotoxic effects in the presence of maternal toxicity in animals.
  2. Disclose an LD50 (mouse, oral) value of 536 mg/kg for the confidential ingredient “quaternized amine 1”.
  3. Disclose an LD50 (rat, oral) value of 0.2g/kg for the confidential ingredient “quaternized amine 2”.

RN: 9616

Date of compliance undertaking: 2016-05-25

The claimant had been advised to amend certain aspects of the wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose an acceptable LD50 (rat, oral) value for the confidential ingredient “organic acid-1”.

RN: 9655

Date of compliance undertaking: 2016-03-15

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of three additional confidential ingredients, “polyether polyol”, “polyolefin amide alkeneamine” and “alkyl benzene”.
  2. Disclose the presence of an additional ingredient, along with its CAS registry number and concentration, or concentration range, in the product.
  3. Disclose an LD50 (rabbit, dermal) value of 2.38 mL/kg for the ingredient “2-ethyl hexanol”.
  4. Disclose that an ingredient has been classified as a suspected carcinogen (2B) by the IARC.
  5. Disclose that an ingredient has been shown to cause skin and eye irritation.

RN: 9656

Date of compliance undertaking: 2016-02-29

The claimant had been advised to amend certain aspects of the wording of the MSDS.

RN: 9658

Date of compliance undertaking: 2016-04-04

The claimant had been advised to amend certain aspects of the wording of the MSDS.

[29-1-o]

DEPARTMENT OF INDUSTRY

OFFICE OF THE REGISTRAR GENERAL

Appointments

Name and position

Order in Council

Cullen, The Hon. Austin F.

2016-642

  • Government of British Columbia
 
  • Administrator
 
  • September 19 to September 23, 2016
 

Dawson, Mary Elizabeth, C.M., Q.C.

2016-661

  • Conflict of Interest and Ethics Commissioner on an interim basis
 

Government of Ontario

2016-640

  • Administrators
 
  • Lauwers, The Hon. Peter D.
 
  • August 19 to August 21, 2016
 
  • Smith, The Hon. Heather J.
 
  • July 15 to July 31 and August 6 to August 14, 2016
 

Government of Quebec

2016-587

  • Administrators
 
  • Giroux, The Hon. Lorne
 
  • July 4 to July 11 and August 10 to August 12, 2016
 
  • Rochette, The Hon. Louis
 
  • June 24 to July 3, 2016
 

Government of Saskatchewan

 
  • Administrators
 
  • Caldwell, The Hon. Neal W.

2016-639

  • July 18 to August 31, 2016
 
  • Herauf, The Hon. Maurice J.

2016-639

  • July 1 to July 17, 2016
 
  • Ryan-Froslie, The Hon. Jacelyn A.

2016-641

  • September 18 to September 24, 2016
 

Hamilton, Bob

2016-585

  • Commissioner of Revenue
 

Shepherd, Karen E.

2016-660

  • Commissioner of Lobbying on an interim basis
 

Tremblay, Christyne

2016-586

  • Deputy Minister of Natural Resources
 

Watson, The Hon. Jack

2016-588

  • Government of Alberta
 
  • Administrator
 
  • July 11 to July 15, 2016
 

Wood, John

2016-658

  • Freshwater Fish Marketing Corporation
 
  • Act as President
 

July 8, 2016

DIANE BÉLANGER
Official Documents Registrar

[29-1-o]

DEPARTMENT OF INDUSTRY

RADIOCOMMUNICATION ACT

Notice No. SMSE-013-16 — Release of CB-01, Issue 5, and CB-02, Issue 7

Notice is hereby given that Innovation, Science and Economic Development Canada (ISED) is releasing the following documents:

All documents will come into force upon their publication on the Department’s Web page, at the following address: http://www.ic.gc.ca/eic/site/smt-gst.nsf/eng/h_sf01841.html.

General information

The Procedures for Conformity Assessment Bodies list will be amended accordingly.

Submitting comments

Interested parties are requested to provide their comments within 90 days of the date of publication of this notice using the online General Inquiry form, at http://www.ic.gc.ca/res_general. Comments and suggestions for improving these standards may be submitted online using the Standard Change Request form, at http://www.ic.gc.ca/res_change.

Obtaining copies

Copies of this notice and of documents referred to herein are available electronically on ISED’s Spectrum Management and Telecommunications Web site at http://www.ic.gc.ca/spectrum.

Official versions of Canada Gazette notices can be viewed at http://www.gazette.gc.ca/rp-pr/p1/index-eng.html.

July 7, 2016

MARTIN PROULX
Acting Director General
Engineering, Planning and Standards Branch

[29-1-o]

PRIVY COUNCIL OFFICE

Appointment opportunities

We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. Moving forward, the Government of Canada will use an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous Canadians and minority groups are properly represented in positions of leadership. We will continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.

The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.

Current opportunities

The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council Appointments Web site (http://www.appointments-nominations.gc.ca/slctnPrcs.asp?menu=1&lang=eng):

Position

Organization

Closing date

Vice-Chairperson (Broadcasting)

Canadian Radio-television and Telecommunications Commission

July 19, 2016

Secretary

National Battlefields Commission

July 19, 2016

Director, Board of Management

Canada Revenue Agency

July 27, 2016

Chairperson

Canadian Cultural Property Export Review Board

July 28, 2016

Chairperson

Freshwater Fish Marketing Corporation

August 2, 2016

President

Freshwater Fish Marketing Corporation

August 2, 2016

Upcoming opportunities

New opportunities that will be posted in the coming weeks:

Position

Organization

Full-time Member

National Energy Board

Chairperson

Patented Medicine Prices Review Board

Member

Patented Medicine Prices Review Board

Ongoing opportunities

Position

Organization

Full-time and Part-time Members (Appeal Division)

Social Security Tribunal

Full-time and Part-time Members (General Division — Income Security Section)

Social Security Tribunal

Full-time and Part-time Members (General Division — Employment Insurance Section)

Social Security Tribunal

[29-1-o]